LPC
DNTH icon

Lion Point Capital’s Dianthus Therapeutics DNTH Stock Holding History

Lion Point Capital’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-284,904
Closed -$3.62M – 32
2023
Q1 		$3.62M Buy
+284,904
New +$3.15M 1.49% 10

Other funds holding DNTH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Lion Point Capital's DNTH Position: Q2 2023 in Review

Lion Point Capital sold out of Dianthus Therapeutics (DNTH) in Q2 2023, closing a stake of 284,904 shares — an estimated $3.62M sold.

Lion Point Capital first reported a position in DNTH in Q1 2023 and held it in 1 quarter. The position peaked at $3.62M in Q1 2023. 46 funds tracked by Wall St. Rank hold DNTH as of Q2 2023.

  • Lion Point Capital reported no remaining Dianthus Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Lion Point Capital sold 284,904 Dianthus Therapeutics shares in Q2 2023, an estimated $3.62M.
  • Lion Point Capital first reported a position in Dianthus Therapeutics in Q1 2023 and held it in 1 quarter.
  • Lion Point Capital's Dianthus Therapeutics position peaked at $3.62M in Q1 2023.
  • 46 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2023.

Based on Lion Point Capital's 13F filing for Q2 2023, filed 14 Aug 2023.